UK Markets open in 4 hrs 46 mins
  • NIKKEI 225

    30,504.75
    +181.41 (+0.60%)
     
  • HANG SENG

    24,702.44
    +34.59 (+0.14%)
     
  • CRUDE OIL

    72.67
    +0.06 (+0.08%)
     
  • GOLD FUTURES

    1,756.10
    -0.60 (-0.03%)
     
  • DOW

    34,751.32
    -63.07 (-0.18%)
     
  • BTC-GBP

    34,764.27
    -266.71 (-0.76%)
     
  • CMC Crypto 200

    1,227.88
    -5.41 (-0.44%)
     
  • Nasdaq

    15,181.92
    +20.42 (+0.13%)
     
  • ^FTAS

    4,051.44
    +12.00 (+0.30%)
     

The Law Offices of Frank R. Cruz Announces Investigation of CorMedix Inc. (CRMD) on Behalf of Investors

  • Oops!
    Something went wrong.
    Please try again later.
·3-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

LOS ANGELES, July 29, 2021--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of CorMedix Inc. ("CorMedix" or the "Company") (NASDAQ: CRMD) on behalf of investors concerning the Company’s possible violations of federal securities laws.

If you are a shareholder who suffered a loss, click here to participate.

In July 2020, CorMedix filed its New Drug Application ("NDA") with the U.S. Food and Drug Administration ("FDA") for DefenCath, an antibacterial and antifungal solution, as a catheter lock solution with an initial indication for use of preventing certain catheter-related bloodstream infections.

On March 1, 2021, CorMedix announced the NDA would not be approved "in its present form" due to "concerns at the third-party manufacturing facility." Moreover, the FDA "is requiring a manual extraction study to demonstrate that the labeled volume can be consistently withdrawn from the vials despite an existing in-process control to demonstrate fill volume within specifications."

On this news, CorMedix’s stock price fell $5.98 per share, or 39.87%, to close at $9.02 per share on March 1, 2021.

Then, on April 14, 2021, CorMedix announced it would have to take additional steps to meet the FDA’s requirements for DefenCath’s manufacturing process, including "[a]ddressing FDA’s concerns regarding the qualification of the filling operation [that] may necessitate adjustments in the process and generation of additional data on operating parameters for manufacture of DefenCath."

On this news, CorMedix’s stock price fell $1.44 per share, or 15.37%, to close at $7.93 per share on April 14, 2021.

Then, on May 13, 2021, CorMedix announced that "[b]ased on our analyses, we have concluded that additional process qualification will be needed with subsequent validation to address the deficiencies identified by FDA." Among other things, the Company was required "to generate sufficient data to demonstrate that [the filling] process is a controlled process and is consistent with the agency’s requirements for good manufacturing practice."

On this news, CorMedix’s stock price fell $1.51 per share, or 19.97%, to close at $6.05 per share on May 14, 2021.

Follow us for updates on Twitter: twitter.com/FRC_LAW.

If you purchased CorMedix securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 1999 Avenue of the Stars, Suite 1100, Los Angeles, California 90067 at 310-914-5007, by email to info@frankcruzlaw.com, or visit our website at www.frankcruzlaw.com. If you inquire by email please include your mailing address, telephone number, and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210728006038/en/

Contacts

The Law Offices of Frank R. Cruz, Los Angeles
Frank R. Cruz, 310-914-5007
fcruz@frankcruzlaw.com
www.frankcruzlaw.com

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting